Biosynthetic Gene Cluster for the Production of Peptide/protein Analogues

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the identification and use of a novel biosynthetic gene cluster that enables the production of unique, highly modified peptide and protein analogues, like polytheonamides, through engineered biosynthetic pathways. The genetic tools and methods disclosed allow the production of these compounds in easily cultivated hosts (e.g., bacteria), overcoming the longstanding supply problem of rare marine peptides and unlocking strategies for synthetic biology to make new bioactive molecules. The patent further covers methods for identifying related gene clusters in other species, the production of modified peptides/proteins with medical relevance, and provides means to make peptide-drug conjugates (e.g., for targeted cancer treatment).

Use CasesContent extracted from patent full text and abstract with AI.

• Biotechnological production of complex, modified peptides (such as polytheonamides) in bacteria or other culturable hosts.
• Development of new peptide- or protein-based drugs for treating disorders like cancer (e.g., use as cytotoxic agents for tumor therapy).
• Creation of peptide-drug conjugates, linking cytotoxic peptides to antibodies or targeting moieties for selective delivery to disease cells (such as tumor cells).
• Screening for, identifying, and exploiting similar biosynthetic gene clusters from other organisms to produce novel natural products or analogues.
• Synthetic biology or protein engineering to generate new peptides and proteins with unprecedented modifications for use in research, diagnostics, or therapeutics.
• Production of pharmaceutical-grade bioactive peptides previously only available in minute amounts from wild sources.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a reliable, scalable, and environmentally-friendly method for producing rare and complex bioactive peptides that are otherwise difficult to source.
• Enables the engineered biosynthesis of new-to-nature peptides with tailored post-translational modifications, expanding chemical and therapeutic diversity.
• Facilitates large-scale, GMP-compliant production of therapeutically valuable peptides (overcoming supply bottlenecks for clinical development).
• Allows for the rational design and manufacture of peptide-protein conjugates or fusion proteins for targeted therapies, improving patient specificity and reducing side effects.
• Opens avenues for drug discovery and development based on natural product analogues with unique modes of action (e.g., ion channel-forming toxins for cancer therapy).
• Provides genetic and bioinformatic tools to identify new biosynthetic pathways, supporting ongoing natural product research and innovation.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A novel gene cluster encoding polypeptides involved in the generation of bio synthetically unique peptide-based compounds is described. In addition, new methods for biosynthetic engineering and production of modified peptides and proteins are disclosed. Furthermore, new tools for identification of homologue polypeptides and precursor peptides in other species are provided. In addition, peptide-based compounds and fusions of these compounds with functional moieties for treatment of disorders such as tumors are disclosed.